Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996034 · ClinicalTrials.gov registry record · Phase 2
Nicotine Vaccination and Nicotinic Receptor Occupancy
A Phase 2 study of Nicotine Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00996034 is a Phase 2 study of Nicotine Dependence that has completed, run by Yale University. The registered enrollment target is 14 participants, below the 187-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00996034, a Phase 2 study of Nicotine Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharmaceuticals. NicVAX (Nicotine Conjugate Vaccine) is an investigational vaccine designed as an aid to smoking cessation and long-term abstinence, as well as an aid to prevent relapses of a treated smoker. In this project we want to understand the degree to which NicVAX administration changes how much nicotine enters the brain in smokers.
Conditions Studied
Interventions
- BIOLOGICAL NicVAX
- RADIATION [123I]5-IA-85380
- DRUG Nicotine bitartrate
Study Locations (1)
Connecticut
- Veterans Association Connecticut Hospital System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996034
The ClinicalTrials.gov registry entry for NCT00996034 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 187-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (93% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 3 interventions - of which NicVAX is the first listed.
NCT00996034 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00996034 about?
NCT00996034 is a clinical study titled "Nicotine Vaccination and Nicotinic Receptor Occupancy". This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharmaceuticals. NicVAX (Nicotine Conjugate Vaccine) is an investigational vaccine designed as an aid to smoking cess...
What is the current status of trial NCT00996034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2009-09. Estimated completion is 2011-02.
What conditions does trial NCT00996034 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT00996034?
The interventions under investigation include: NicVAX (BIOLOGICAL), [123I]5-IA-85380 (RADIATION), Nicotine bitartrate (DRUG).
Who is sponsoring clinical trial NCT00996034?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00996034 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Varenicline for E-cigarette Cessation
RECRUITING · Phase 2
-
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
COMPLETED · Phase 2
-
N-acetylcysteine for Tobacco Use Disorder
COMPLETED · Phase 2
-
Targeted Interventions for Weight-Concerned Smokers
COMPLETED · Phase 2
-
Adaptive Pharmacotherapy for Smoking Cessation
COMPLETED · Phase 2
-
E-cigarette Nicotine Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.